Protein / target
Placenta growth factor
Protein at a glance
Biological role
Vascular endothelial growth factor receptor binding
Primary system
Cardiovascular system
Strongest disease association
diabetic macular edema
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
1 approved · 2 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Growth factor active in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. Isoform PlGF-2 binds NRP1/neuropilin-1 and NRP2/neuropilin-2 in a heparin-dependent manner. Also promotes cell tumor growth
Subcellular location
Domains and Gene Ontology detail (18)Hide
Gene Ontology
- Cextracellular region
- Cextracellular space
- Cmembrane
- Fchemoattractant activity
- Fgrowth factor activity
- Fheparin binding
- Fvascular endothelial growth factor receptor binding
- Pcell differentiation
- Pcell-cell signaling
- Pinduction of positive chemotaxis
- Ppositive regulation of cell division
- Ppositive regulation of cell population proliferation
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·positive regulation of mast cell chemotaxis
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Placenta growth factor inhibitor
Appears in clinical studies involving macular degeneration, retinal vein occlusion, colorectal cancer, choroidal neovascularization
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 954 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 3 total
diabetic macular edema · choroidal neovascularization · macular retinal edema
macular degeneration · retinal vein occlusion · colorectal cancer
brain glioblastoma · neoplasm · ovarian cancer
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Regulatory approval
Approval: Eyluxvi (EMA)
- Regulatory approval
Approval: Mynzepli (EMA)
- Regulatory approval
Approval: Afiveg (EMA)
- Regulatory approval
Approval: Vgenfli (EMA)
- Regulatory approval
Approval: Eiyzey (EMA)
- Regulatory approval
Approval: Eydenzelt (EMA)
- Regulatory approval
Approval: Baiama (EMA)
- Regulatory approval
Approval: Ahzantive (EMA)
- Regulatory approval
Approval: Afqlir (EMA)
- Regulatory approval
Approval: Opuviz (EMA)
- Product recall
Recall (Class II): AFLIBERCEPT
- New publicationFirst-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.